CA-MIDEA-GROUP
10.7.2024 10:51:29 CEST | Business Wire | Press release
Midea Group, recognized as a leading global technology and innovation enterprise, has successfully completed its 1H 2024 Campus Recruitment Tour with the final event on July 6th at Stanford University. These recruitment activities also represent a significant step in the company's ongoing pursuit of global expansion and the strategic localization of innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709152530/en/
Midea Group's 2024 1H Overseas Campus Recruitment Tour at Stanford University (Photo: Business Wire)
With a diverse portfolio encompassing smart home solutions, industrial technology, building technology, robotics and automation, and innovative businesses, Midea Group has reaffirmed its dedication to global markets through this comprehensive recruitment initiative. Every year, approximately 15-20% of Midea Group's campus recruits have overseas study backgrounds, significantly enriching the company's international talent pool.
Highlights of the 2024 Midea Campus Recruitment:
- Over 3000 candidates participated in the event
- Over 4 countries and 20 engaging campus offline events conducted
- Over 10 specialized roundtables tailored for doctoral candidates
In-Depth Strategic Sessions:
- Leadership Insights: Keynote sessions led by Midea's CTO, CPO, and other executives provided visionary perspectives on the future of technology and Midea's pivotal role.
- Cultural Deep Dive: Emphasizing Midea's people-centric philosophy, the sessions highlighted the company's commitment to employee wellness, benefits, and personal growth.
- Innovation Showcase: Featuring Midea's expansive R&D network, including the Central Research Institute driving the "2+4+N" global R&D strategy, solidifying Midea's leadership in technological innovation.
Interactive and Immersive Experiences:
- Q&A Sessions: Transparent discussions on Midea's values, opportunities, and expectations.
- Roundtable Discussions: In-depth dialogues on R&D initiatives, career growth, and global presence.
- Alumni Sharing: Personal growth stories from alumni provided firsthand insights into career opportunities within Midea.
A Clear Path to Recruitment:
- Overseas Students Exclusive Channel: Overseas students graduating from January 2024 to December 2025 are all our target candidates and are allowed to submit resumes online.
- Process Clarity: Candidates were guided through a transparent application, interview, and job offer process.
- Diverse Opportunities: Roles spanning R&D, AI, IT, engineering, and more showcased Midea's commitment to diverse skill sets and professional interests.
- Global Outlook: With opportunities in over 40 global cities, Midea offered candidates a chance to work in multicultural environments.
Midea's Ongoing Commitment
From the UK to Germany, Japan, and the United States, Midea's 1H 2024 recruitment journey underscores its steadfast commitment to creating an innovative, inclusive, and open-minded platform. The company continues to invest significantly in its people and R&D, ensuring it remains at the forefront of technological advancement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709152530/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom